Abstract
Primary dysmenorrhea (PD), characterised by chronic pelvic pain during menstruation, significantly impairs the quality of life for many women. This paper presents a modelling and clinical validation study of the novel Nettle™ device for at-home transcranial direct current stimulation (tDCS) for alleviating PD symptoms. Specifically, we aimed to investigate the electric field patterns induced by Nettle™ and its immediate efficacy in reducing menstrual pain and improving functionality. Finite element method (FEM) simulations, using realistic head models, assessed the electric field distribution, targeting key brain regions involved in pain processing. A single-centre triple-blinded, sham-controlled study involving 34 women was conducted to compare the effects of active and sham tDCS. Results demonstrated a clinically meaningful decline in menstrual pain symptoms in the active group, with medium effect sizes for both pain reduction (Cohen’s d=0.53) and functionality (Cohen’s d=0.47), based on Nettle™’s protocol focused on the electric field within the medial prefrontal cortex. Limitations include the use of generalised brain models and small sample size, highlighting the need for further research with comprehensive modelling and larger clinical trials to validate and understand the effects of Nettle™ as a menstrual neuromodulation therapy.
Clinical Relevance This study underscores Nettle™’s potential as a non-invasive, cost-efficient intervention for PD, with implications for broader applications in women’s health.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Brazilian Clinical Trials Registry (RBR-56w7h2p). Trial identification UTN code:U1111-1282-0975.
Funding Statement
The clinical validation work of this study was funded by Prof Rodrigo Pegado and Prof Maria Thereza Micussi at the Federal University of Rio Grande do Norte. The modelling work was funded by grant funding to Samphire Neuroscience Ltd from UK Research & Innovation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Federal University of Rio Grande do Norte (UFRN) gave ethical approval of this work under number 5.508.364.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
em{at}samphireneuro.com
laura{at}samphireneuro.com
ervinas{at}samphireneuro.com
alex{at}samphireneuro.com
mmicussi{at}bwh.harvard.edu
rodrigo{at}facisa.ufrn.br
The clinical validation work was supported by the funding of Prof Rodrigo Pegado and Prof Maria Thereza Micussi at the Federal University of Rio Grande do Norte. The modelling work was supported by grant funding to Samphire Neuroscience Ltd from UK Research & Innovation.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
